Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection

Detalhes bibliográficos
Autor(a) principal: Vaz,Sara Nunes
Data de Publicação: 2020
Outros Autores: Santana,Daniele Souza de, Netto,Eduardo Martins, Pedroso,Celia, Wang,Wei-Kung, Santos,Felice Deminco Alves, Brites,Carlos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Infectious Diseases
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702020000500422
Resumo: Abstract Background Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease 2019 (COVID-19). Although Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) of respiratory specimens is the gold standard test for detection of SARS-CoV-2 infection, collecting nasopharyngeal swabs causes discomfort to patients and may represent considerable risk for healthcare workers. The use of saliva as a diagnostic sample has several advantages. Objectives The aim of this study was to validate the use of saliva as a biological sample for diagnosis of COVID-19. Methods This study was conducted at Infectious Diseases Research Laboratory (LAPI), in Salvador, Brazil. Participants presenting with signs/symptoms suggesting SARS-CoV-2 infection underwent a nasopharyngeal swab (NPS) and/or oropharyngeal swab (OPS), and saliva collection. Saliva samples were diluted in PBS, followed by RNA isolation and RT-Real Time PCR for SARS-CoV-2. Results of conventional vs saliva samples testing were compared. Statistical analyses were performed using Statistical Package for the Social Sciences software (SPSS) version 18.0. Results One hundred fifty-five participants were recruited and samples pairs of NPS/OPS and saliva were collected. The sensitivity and specificity of RT-PCR using saliva samples were 94.4% (95% CI 86.4–97.8) and 97.62% (95% CI 91.7–99.3), respectively. There was an overall high agreement (96.1%) between the two tests. Conclusions Use of self-collected saliva samples is an easy, convenient, and low-cost alternative to conventional NP swab-based molecular tests. These results may allow a broader use of molecular tests for management of COVID19 pandemic, especially in resources-limited settings.
id BSID-1_e8fe1a0732de6226358e4cd3ef489018
oai_identifier_str oai:scielo:S1413-86702020000500422
network_acronym_str BSID-1
network_name_str Brazilian Journal of Infectious Diseases
repository_id_str
spelling Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detectionSARS-CoV-2COVID-19salivaDiagnosticsAbstract Background Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease 2019 (COVID-19). Although Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) of respiratory specimens is the gold standard test for detection of SARS-CoV-2 infection, collecting nasopharyngeal swabs causes discomfort to patients and may represent considerable risk for healthcare workers. The use of saliva as a diagnostic sample has several advantages. Objectives The aim of this study was to validate the use of saliva as a biological sample for diagnosis of COVID-19. Methods This study was conducted at Infectious Diseases Research Laboratory (LAPI), in Salvador, Brazil. Participants presenting with signs/symptoms suggesting SARS-CoV-2 infection underwent a nasopharyngeal swab (NPS) and/or oropharyngeal swab (OPS), and saliva collection. Saliva samples were diluted in PBS, followed by RNA isolation and RT-Real Time PCR for SARS-CoV-2. Results of conventional vs saliva samples testing were compared. Statistical analyses were performed using Statistical Package for the Social Sciences software (SPSS) version 18.0. Results One hundred fifty-five participants were recruited and samples pairs of NPS/OPS and saliva were collected. The sensitivity and specificity of RT-PCR using saliva samples were 94.4% (95% CI 86.4–97.8) and 97.62% (95% CI 91.7–99.3), respectively. There was an overall high agreement (96.1%) between the two tests. Conclusions Use of self-collected saliva samples is an easy, convenient, and low-cost alternative to conventional NP swab-based molecular tests. These results may allow a broader use of molecular tests for management of COVID19 pandemic, especially in resources-limited settings.Brazilian Society of Infectious Diseases2020-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702020000500422Brazilian Journal of Infectious Diseases v.24 n.5 2020reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1016/j.bjid.2020.08.001info:eu-repo/semantics/openAccessVaz,Sara NunesSantana,Daniele Souza deNetto,Eduardo MartinsPedroso,CeliaWang,Wei-KungSantos,Felice Deminco AlvesBrites,Carloseng2020-11-26T00:00:00Zoai:scielo:S1413-86702020000500422Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2020-11-26T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false
dc.title.none.fl_str_mv Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection
title Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection
spellingShingle Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection
Vaz,Sara Nunes
SARS-CoV-2
COVID-19
saliva
Diagnostics
title_short Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection
title_full Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection
title_fullStr Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection
title_full_unstemmed Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection
title_sort Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection
author Vaz,Sara Nunes
author_facet Vaz,Sara Nunes
Santana,Daniele Souza de
Netto,Eduardo Martins
Pedroso,Celia
Wang,Wei-Kung
Santos,Felice Deminco Alves
Brites,Carlos
author_role author
author2 Santana,Daniele Souza de
Netto,Eduardo Martins
Pedroso,Celia
Wang,Wei-Kung
Santos,Felice Deminco Alves
Brites,Carlos
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Vaz,Sara Nunes
Santana,Daniele Souza de
Netto,Eduardo Martins
Pedroso,Celia
Wang,Wei-Kung
Santos,Felice Deminco Alves
Brites,Carlos
dc.subject.por.fl_str_mv SARS-CoV-2
COVID-19
saliva
Diagnostics
topic SARS-CoV-2
COVID-19
saliva
Diagnostics
description Abstract Background Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease 2019 (COVID-19). Although Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) of respiratory specimens is the gold standard test for detection of SARS-CoV-2 infection, collecting nasopharyngeal swabs causes discomfort to patients and may represent considerable risk for healthcare workers. The use of saliva as a diagnostic sample has several advantages. Objectives The aim of this study was to validate the use of saliva as a biological sample for diagnosis of COVID-19. Methods This study was conducted at Infectious Diseases Research Laboratory (LAPI), in Salvador, Brazil. Participants presenting with signs/symptoms suggesting SARS-CoV-2 infection underwent a nasopharyngeal swab (NPS) and/or oropharyngeal swab (OPS), and saliva collection. Saliva samples were diluted in PBS, followed by RNA isolation and RT-Real Time PCR for SARS-CoV-2. Results of conventional vs saliva samples testing were compared. Statistical analyses were performed using Statistical Package for the Social Sciences software (SPSS) version 18.0. Results One hundred fifty-five participants were recruited and samples pairs of NPS/OPS and saliva were collected. The sensitivity and specificity of RT-PCR using saliva samples were 94.4% (95% CI 86.4–97.8) and 97.62% (95% CI 91.7–99.3), respectively. There was an overall high agreement (96.1%) between the two tests. Conclusions Use of self-collected saliva samples is an easy, convenient, and low-cost alternative to conventional NP swab-based molecular tests. These results may allow a broader use of molecular tests for management of COVID19 pandemic, especially in resources-limited settings.
publishDate 2020
dc.date.none.fl_str_mv 2020-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702020000500422
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702020000500422
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.bjid.2020.08.001
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
dc.source.none.fl_str_mv Brazilian Journal of Infectious Diseases v.24 n.5 2020
reponame:Brazilian Journal of Infectious Diseases
instname:Brazilian Society of Infectious Diseases (BSID)
instacron:BSID
instname_str Brazilian Society of Infectious Diseases (BSID)
instacron_str BSID
institution BSID
reponame_str Brazilian Journal of Infectious Diseases
collection Brazilian Journal of Infectious Diseases
repository.name.fl_str_mv Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)
repository.mail.fl_str_mv bjid@bjid.org.br||lgoldani@ufrgs.br
_version_ 1754209245107060736